Literature DB >> 8908502

Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors.

R S Coffin1, A R MacLean, D S Latchman, S M Brown.   

Abstract

Herpes simplex virus 1 (HSV1) ICP34.5 deletion mutants are avirulent upon inoculation of both the central and peripheral nervous systems of mice, but they replicate to near wild-type titres in a number of non-neuronally derived cell lines in culture. Thus these mutants might be suitable for development as safe vectors for gene transfer to the nervous system. However, the mechanism of this avirulent phenotype in neuronal cells is at present poorly understood, although it has been suggested that nonpermissive cells infected with these mutants may undergo apoptosis, the function of ICP34.5 being to prevent this response and to allow continued virus replication. If this were the case ICP34.5 null mutants might be unsuitable for gene transfer as infected cells would quickly die, limiting the expression of a transgene. Here we have inserted a beta-galactosidase marker gene into a nonessential gene of an HSV1 strain 17+ mutant in which ICP34.5 has been deleted and also into a second mutant in which the virion transactivator protein VMW65 is also inactive. While all the mutants grew to high titre in tissue culture, mice inoculated by the foot-pad or intracranial route at high titre remained healthy until the end of the experiment. Moreover, beta-galactosidase was expressed either in the brain or in the dorsal root ganglia, depending on the site of inoculation. This suggests that in vivo the absence of ICP34.5 does not prevent the expression of a transgene in neuronal tissue and indicates that non-neurovirulent mutants lacking this gene may be suitable for further development as safe vectors for gene therapy in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8908502

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system.

Authors:  D S Latchman
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

3.  Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

Authors:  J A Palmer; R H Branston; C E Lilley; M J Robinson; F Groutsi; J Smith; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  HSV.com: maneuvering the internetworks of viral neuropathogenesis and evasion of the host defense.

Authors:  S L Tan; M G Katze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.

Authors:  Laila Samady; Emanuela Costigliola; Luci MacCormac; Yvonne McGrath; Steve Cleverley; Caroline E Lilley; Jill Smith; David S Latchman; Benny Chain; Robert S Coffin
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 6.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

7.  L Particles Transmit Viral Proteins from Herpes Simplex Virus 1-Infected Mature Dendritic Cells to Uninfected Bystander Cells, Inducing CD83 Downmodulation.

Authors:  Christiane S Heilingloh; Mirko Kummer; Petra Mühl-Zürbes; Christina Drassner; Christoph Daniel; Monika Klewer; Alexander Steinkasserer
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

8.  Gene delivery to rat enteric neurons using herpes simplex virus-based vectors.

Authors:  M K Howard; R S Coffin; A R Maclean; S M Brown; D Bailey; P N Anderson; G Burnstock; D S Latchman
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

9.  Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects.

Authors:  S K Thomas; C E Lilley; D S Latchman; R S Coffin
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

10.  Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.

Authors:  Eeva K Broberg; Jutta Peltoniemi; Michaela Nygårdas; Tero Vahlberg; Matias Röyttä; Veijo Hukkanen
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.